Does Antares Pharma (NASDAQ:ATRS) Look Attractive Now? Chardan Capital Initiates Coverage

Angelica Greene
June 27, 2017

The Stock traded with an actual day volume of 19.91 Million and average volume of 1.36 Million respectively. (NASDAQ:ATRS) is 37.77%, 16.30% over the last quarter, and 38.96% for the past six months. Conocophillips Com now has $55.48 billion valuation. The stock declined 2.18% or $0.07 reaching $3.14 per share. About 126,154 shares traded. It has underperformed by 7.20% the S&P500. Analysts are forecasting earnings of $-0.03 on a per share basis this quarter. Therefore 100% are positive.

A look at some of the inputs to technical analysis model shows how Antares Pharma, Inc. current price compares to its recent moving averages. The stock inclined 4.83% last month and is up 3.80 this year. JACOB LEONARD S also sold $120,682 worth of Antares Pharma Inc (NASDAQ:ATRS) shares. On Friday, October 23 the stock rating was downgraded by Barclays Capital to "Underweight". Following the completion of the transaction, the chief executive officer now directly owns 927,002 shares in the company, valued at $2,781,006. Janus Ltd owns 186,149 shares. The disclosure for this purchase can be found here. McMorran James D sold $431,590 worth of stock or 9,091 shares. Vanguard Group has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Therefore 68% are positive. The firm has "Neutral" rating by Bank of America given on Thursday, May 11. Jefferies maintained the stock with "Buy" rating in Wednesday, March 9 report. H.C. Wainwright has "Buy" rating and $5 target. (NASDAQ:ECHO) on Tuesday, December 20 with "Neutral" rating.

This stock is ahead of its 52-week low with +29.31%. The firm earned "Neutral" rating on Monday, July 11 by UBS.

Analysts await ConocoPhillips (NYSE:COP) to report earnings on July, 27. (ATRS) is its Earnings per Share or EPS. COP's profit will be $173.26 million for 80.05 P/E if the $0.14 EPS becomes a reality.

A number of equities analysts have recently issued reports on ATRS shares. Its down 0.24, from 1.44 in 2016Q3. It dropped, as 55 investors sold COP shares while 525 reduced holdings. Powell Fred M also bought $363,272 worth of Antares Pharma Inc (NASDAQ:ATRS) shares.

Croft-Leominster Inc decreased Telephone & Data Sys Inc (Prn) (NYSE:TDS) stake by 14,397 shares to 194,033 valued at $5.60M in 2016Q4. John G Ullman has invested 1.39% in ConocoPhillips (NYSE:COP). Cap One National Association stated it has 0.05% in ConocoPhillips (NYSE:COP). Tru Inv Advisors Ltd Liability accumulated 51,111 shares. Renaissance Limited Liability holds 2.86 million shares or 0.01% of its portfolio. The 7 months bullish chart indicates low risk for the $518.81M company. Etrade Cap Mgmt Limited Liability Company owns 39,838 shares. Cortina Asset Management Ltd Co invested in 476,571 shares. Understanding the market cap is not just important if you "almost investing directly in stocks". The stock had previously closed at $2.66, but opened at $2.78. KCG Holdings Inc. raised its position in Antares Pharma by 48.8% in the first quarter. It has outperformed by 190.44% the S&P500.

Since March 31, 2017, it had 1 insider buy, and 3 sales for $35,244 activity.

US Student Hospitalized After Return From NKorea
A Department of State spokeswoman said that out of respect for the privacy of Warmbier's family, "we have no further comment". He was arrested in January 2016 and accused of trying to steal a propaganda poster from an employee area of his hotel.

Amazon's $14-Billion Grocery Deal a 'Threat' to Food Retailers
Traditional grocers like Safeway and Kroger are particularly vulnerable to an aggressive play by Amazon into the grocery sector. Amazon also has been testing automation technology at a Seattle convenience store that's now open only to Amazon employees.

Apple CEO Tim Cook talked to Trump about immigration
Trump on Monday cited estimates that the government could save up to $1 trillion over 10 years through such measures. Only the founder of Facebook, Mark Zuckerberg , was unable to attend after being invited.

In other Antares Pharma news, CEO Robert F. Apple sold 40,000 shares of the stock in a transaction that occurred on Wednesday, April 5th.

Over the past 50 days, Antares Pharma, Inc. stock's -0.93% off of the high and 36.60% removed from the low.

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has a market cap of $318.90M and its 12 month revenue was nearly $2.80M. The Firm develops, makes and commercializes therapeutic products using its drug delivery systems. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Investors sentiment increased to 0.96 in Q4 2016. Its down 0.29, from 1.29 in 2016Q3. 9 funds opened positions while 16 raised stakes.

Antares Pharma Cmn (NASDAQ:ATRS) now has a trailing P/E of -23.26 while its forward P/E according to Thomson Reuters is 160.5. J Goldman Company L P stated it has 181,500 shares. Brown Advisory Secs Lc owns 275,000 shares. First Eagle Invest Management Limited Liability Corporation has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Perceptive Advsrs Ltd Llc reported 2.92M shares stake. Bancorp Of Ny Mellon invested in 0% or 139,486 shares. Oppenheimer And Inc invested in 0.01% or 75,900 shares. Alyeska Group Inc Limited Partnership, Illinois-based fund reported 920,931 shares. (NASDAQ:ATRS) was up 6.64% at $3.21 on Saturday, in a 52-week range of $0.92 to $3.24 and with a consensus analyst target price of $4.58.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by GizPress

Discuss This Article

FOLLOW OUR NEWSPAPER